Macrogen, Inc. Certified as NimbleGen Array Service Provider for Korea

MADISON, Wis.--(BUSINESS WIRE)-- Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) announced today that Seoul-based genomic services provider Macrogen, Inc. has officially joined the Roche NimbleGen Certified Service Provider (CSP) Program. Macrogen has been certified to process customer samples for NimbleGen Comparative Genomic Hybridization/Copy Number Variation (CGH/CNV) services in their lab in Seoul. As a CSP, Macrogen will process gDNA samples for CGH/CNV using the complete NimbleGen array CGH workflow which includes the high-resolution NimbleGen MS 200 Microarray Scanner. Due to the company’s previous experience using NimbleGen arrays and their certification as a service provider, Macrogen will be able to provide an extremely high level of array service to customers for high-throughput array and data processing. Macrogen had successfully finished the Korea Centers for Disease Control and Prevention (KCDC) CNV projects using Roche NimbleGen aCGH microarrays in 2009. The KCDC CNV project was two-phase study including large-scale characterization of CNVs in Korean populations and analysis of common CNVs in genome-wide association studies for 6,000 Korean individuals.

CGH is an important tool that allows the detection of chromosomal abnormalities, copy number variations, and specific break-points at much higher resolution over conventional methods. The genome-wide and disease associated region focused research that this technology provides on these types of chromosomal phenomenon has the potential to bring significant advances into the development of personalized healthcare options in the future.

“Macrogen is a leading service provider for CNV analysis based on several significant studies completed including the KCDC project targeting Korean-specific CNVs as well as the world’s first high-definition Asian CNV map.” said Dr. Hyungtae Kim, CEO of Macrogen. “I believe that Roche NimbleGen’s CGH/CNV microarrays allow Macrogen to remain at the cutting-edge with the latest technologies for CNV studies to provide our customers with a leading microarray service.”

“Roche NimbleGen is extremely pleased to welcome Macrogen as our first certified service provider in Korea for the CGH/CNV application. We look to build on our recent KCDC collaboration with Macrogen, which used our high resolution CNV arrays, to strengthen our global position in the field of copy number variation detection" said Dr. Frank Pitzer, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit www.nimblegen.com

About Roche
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2009, Roche had over 80’000 employees worldwide and invested almost 10 billion Swiss francs in R&D. The Group posted sales of 49.1 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

About Macrogen
Macrogen, Inc., Seoul Korea, a world leading service provider in the high-quality gene analysis, has enjoyed stable and steady growth since 1997 and gained worldwide recognition as a bioengineering company offering comprehensive services in genetic information analysis. Knowing that the 21st century medical revolution requires new genomic-based tools, the company has dedicated itself to providing the fundamental research and development tools such as bioinformatics infrastructure for genetic information analysis and functional genomics. The company offers DNA sequencing, next generation sequencing, microarray service and analysis, and genetically engineered mice services. In addition, Macrogen has been actively expanding its business scope into molecular diagnostics and personal genomics. With a global presence, Macrogen operates through its subsidiaries in Rockville, MD in the U.S., in The Netherlands in Europe, and in Tokyo, Japan. Macrogen is listed on the Korea Securities Dealers Automated Quotation (ticker symbol: A038290). For more information, visit www.macrogen.com.

For life science research only. Not for use in diagnostic procedures.
NIMBLEGEN is a trademark of Roche.
Other brands or product names are trademarks of their respective holders.



CONTACT:

Roche Diagnostics
Dr. Burkhard Ziebolz
Phone: +49 8856 604830
Email: [email protected]
or
Roche NimbleGen
Kary Staples
Phone: +1 608 218 7623
Email: [email protected]

KEYWORDS:   United States  Europe  Asia Pacific  North America  South Korea  Switzerland  Wisconsin  Japan

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical  Other Health

MEDIA:

Logo
 Logo

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.